Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients
Ronald Jan Corbee, Dion L. van Everdingen, H.S. Kooistra, Louis C. Penning
Abstract
Fibroblast growth factors (FGFs) are involved in numerous metabolic processes. The endocrine subfamily of FGFs, consisting of FGF19, FGF21, and FGF23, might have beneficial effects in the treatment of diabetes mellitus (DM) and/or obesity. The analog with the greatest potential, FGF21, lowers blood glucose levels, improves insulin sensitivity, and induces weight loss in several animal models. In this review we summarize recent (pre)clinical findings with FGF21 analogs in animal models and men. Furthermore, possible applications of FGF21 analogs for pets with DM will be discussed. As currently, information about the use of FGF21 analogs in pet animals is scarce.
Topics & Concepts
FGF21FGF19Fibroblast growth factorDiabetes mellitusObesityFibroblast growth factor 23MedicineEndocrine systemWeight lossEndocrinologyBioinformaticsBiologyInternal medicineHormoneReceptorCalciumParathyroid hormoneFibroblast Growth Factor ResearchKruppel-like factors researchEpigenetics and DNA Methylation